Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action

PARP inhibitors: the race is on

(2016) Jessica S Brown et al.   BRITISH JOURNAL OF CANCER

Repair Pathway Choices and Consequences at the Double-Strand Break

(2016) Raphael Ceccaldi et al.   TRENDS IN CELL BIOLOGY

Nuclear ADP-Ribosylation and Its Role in Chromatin Plasticity, Cell Differentiation, and Epigenetics

(2015) Michael O. Hottiger   Annual Review of Biochemistry

Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors

(2015) Christopher J. Lord et al.   Annual Review of Medicine

Activity-Induced DNA Breaks Govern the Expression of Neuronal Early-Response Genes

(2015) Ram Madabhushi et al.   CELL

A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation — An NRG Oncology/Gynecologic Oncology Group study

(2015) Robert L. Coleman et al.   GYNECOLOGIC ONCOLOGY

Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development

(2015) Clare L. Scott et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System

(2015) K. E. Parrish et al.   MOLECULAR CANCER THERAPEUTICS

Structures and Mechanisms of Enzymes Employed in the Synthesis and Degradation of PARP-Dependent Protein ADP-Ribosylation

(2015) Eva Barkauskaite et al.   MOLECULAR CELL

PARP1- and CTCF-Mediated Interactions between Active and Repressed Chromatin at the Lamina Promote Oscillating Transcription

(2015) Honglei Zhao et al.   MOLECULAR CELL

Targeting the DNA Damage Response in Cancer

(2015) Mark J. O’Connor   MOLECULAR CELL

Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair

(2015) Raphael Ceccaldi et al.   NATURE

Mammalian polymerase θ promotes alternative NHEJ and suppresses recombination

(2015) Pedro A. Mateos-Gomez et al.   NATURE

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

(2015) Joaquin Mateo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Readers of poly(ADP-ribose): designed to be fit for purpose

(2015) Federico Teloni et al.   NUCLEIC ACIDS RESEARCH

Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer

(2015) Linda Henneman et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The DNA repair endonuclease Mus81 facilitates fast DNA replication in the absence of exogenous damage

(2015) Haiqing Fu et al.   Nature Communications

Identification of novel PARP inhibitors using a cell-based TDP1 inhibitory assay in a quantitative high-throughput screening platform

(2014) Junko Murai et al.   DNA REPAIR

Protein ADP-ribosylation and the cellular response to DNA strand breaks

(2014) K.W. Caldecott   DNA REPAIR

CtIP-mediated resection is essential for viability and can operate independently of BRCA1

(2014) Federica Polato et al.   JOURNAL OF EXPERIMENTAL MEDICINE

PARP Inhibitors as P-glyoprotein Substrates

(2014) Denise Lawlor et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

PARP-2 and PARP-3 are selectively activated by 5′ phosphorylated DNA breaks through an allosteric regulatory mechanism shared with PARP-1

(2014) Marie-France Langelier et al.   NUCLEIC ACIDS RESEARCH

PARP1–TDP1 coupling for the repair of topoisomerase I–induced DNA damage

(2014) Benu Brata Das et al.   NUCLEIC ACIDS RESEARCH

Parp-2 is required to maintain hematopoiesis following sublethal  -irradiation in mice

(2013) J. Farres et al.   BLOOD

Function of BRCA1 in the DNA Damage Response Is Mediated by ADP-Ribosylation

(2013) Mo Li et al.   CANCER CELL

A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation

(2013) Ruth Plummer et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity

(2013) I. Bajrami et al.   CANCER RESEARCH

BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency

(2013) Y. Shen et al.   CLINICAL CANCER RESEARCH

Role of Expression Profiling in Carcinoma of Unknown Primary Remains Unknown

(2013) Leonard B. Saltz   JOURNAL OF CLINICAL ONCOLOGY

Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond

(2013) Nicola J. Curtin et al.   MOLECULAR ASPECTS OF MEDICINE

Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib

(2013) J. Murai et al.   MOLECULAR CANCER THERAPEUTICS

Differential and Common DNA Repair Pathways for Topoisomerase I- and II-Targeted Drugs in a Genetic DT40 Repair Cell Screen Panel

(2013) Y. Maede et al.   MOLECULAR CANCER THERAPEUTICS

Proteome-wide Identification of Poly(ADP-Ribosyl)ation Targets in Different Genotoxic Stress Responses

(2013) Stephanie Jungmichel et al.   MOLECULAR CELL

Human RECQ1 promotes restart of replication forks reversed by DNA topoisomerase I inhibition

(2013) Matteo Berti et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Drugging Topoisomerases: Lessons and Challenges

(2012) Yves Pommier   ACS Chemical Biology

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

(2012) J. Murai et al.   CANCER RESEARCH

Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells

(2012) Ilirjana Bajrami et al.   EMBO Molecular Medicine

Activation of the SNF2 Family ATPase ALC1 by Poly(ADP-ribose) in a Stable ALC1·PARP1·Nucleosome Intermediate

(2012) Aaron J. Gottschalk et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Topoisomerase I poisoning results in PARP-mediated replication fork reversal

(2012) Arnab Ray Chaudhuri et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

ADP-ribose polymers localized on Ctcf–Parp1–Dnmt1 complex prevent methylation of Ctcf target sites

(2011) Michele Zampieri et al.   BIOCHEMICAL JOURNAL

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

(2011) Karen A Gelmon et al.   LANCET ONCOLOGY

PARP-3 and APLF Function Together to Accelerate Nonhomologous End-Joining

(2011) Stuart L. Rulten et al.   MOLECULAR CELL

Temozolomide: Mechanisms of Action, Repair and Resistance

(2011) Jihong Zhang et al.   Current Molecular Pharmacology

53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks

(2010) Samuel F. Bunting et al.   CELL

DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs

(2010) Yves Pommier et al.   CHEMISTRY & BIOLOGY

Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses inBRCACarrier Ovarian Cancer Correlating With Platinum-Free Interval

(2010) Peter C. Fong et al.   JOURNAL OF CLINICAL ONCOLOGY

Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate

(2010) C. E. Strom et al.   NUCLEIC ACIDS RESEARCH

Poly(ADP-Ribose) Polymerase-1 Inhibitor Treatment Regresses Autochthonous Brca2/p53-Mutant Mammary Tumors In vivo and Delays Tumor Relapse in Combination with Carboplatin

(2009) T. Hay et al.   CANCER RESEARCH

PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination

(2009) Helen E Bryant et al.   EMBO JOURNAL

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE

Poly(ADP-ribose)-Dependent Regulation of DNA Repair by the Chromatin Remodeling Enzyme ALC1

(2009) D. Ahel et al.   SCIENCE

Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors

(2008) R. Plummer et al.   CLINICAL CANCER RESEARCH

Poly(ADP-ribose) Binds to the Splicing Factor ASF/SF2 and Regulates Its Phosphorylation by DNA Topoisomerase I

(2008) Maria Malanga et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair

(2008) Alan Ashworth   JOURNAL OF CLINICAL ONCOLOGY

Resistance to therapy caused by intragenic deletion in BRCA2

(2008) Stacey L. Edwards et al.   NATURE

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

(2008) S. Rottenberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA